Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - January 22, 2025 572 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source RELATED ARTICLESMORE FROM AUTHOR Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer MOST POPULAR First Global Estimates of Cervical Cancer Attributable to HIV November 30, 2020 27-Year-Old Fighting Stage IV Cancer Gets Hit By COVID-19 And Sepsis... May 29, 2020 FDA Approves HPV Tests That Allow for Self-Collection in a Health... July 24, 2024 EMA Recommends Extension of Indications for Lorlatinib December 20, 2021 Load more HOT NEWS People who’ve had radiotherapy shape our new policy calls ΚΑΡΚΙΝΟΣ ΟΥΡΟΔΟΧΟΥ ΚΥΣΤΕΩΣ A celebration of peer review Screen-Detected Colorectal Cancers Have a More Favourable Stage Distribution than Colorectal...
